Justyna Kocik-Krol

1.2k citations

18 papers · 800 indexed · h-index 10

Oncology top 5%
Immunology top 10%
Molecular Biology
Radiology, Nuclear Medicine and Imaging top 10%
Organic Chemistry

Co-authors: Tad A. Holak Łukasz Skalniak Katarzyna Magiera‐Mularz Bogdan Musielak Dominik Sala Jacek Plewka P. Grudnik Alexander Dömlingꝉ
Topics: Cancer Immunotherapy and Biomarkers (13 papers)CAR-T cell therapy research (11 papers)Peptidase Inhibition and Analysis (6 papers)
Cited by: Oncology Immunology Radiology, Nuclear Medicine and Imaging
Journals: Angewandte Chemie International Edition International Journal of Molecular Sciences Journal of Medicinal Chemistry
Partner nations: Poland Netherlands Hungary

In The Last Decade

Justyna Kocik-Krol

16 papers receiving 788 citations

Peers

Countries citing papers authored by Justyna Kocik-Krol

Since Specialization

Citations

This map shows the geographic impact of Justyna Kocik-Krol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Justyna Kocik-Krol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Justyna Kocik-Krol more than expected).

Fields of papers citing papers by Justyna Kocik-Krol

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Justyna Kocik-Krol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Justyna Kocik-Krol. The network helps show where Justyna Kocik-Krol may publish in the future.

Co-authorship network of co-authors of Justyna Kocik-Krol

This figure shows the co-authorship network connecting the top 25 collaborators of Justyna Kocik-Krol. A scholar is included among the top collaborators of Justyna Kocik-Krol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Justyna Kocik-Krol. Justyna Kocik-Krol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	Characterization of Clinically Evaluated Small-Molecule Inhibitors of PD-L1 for Immunotherapy 2025 ·ACS Medicinal Chemistry Letters ·(unknown),(unknown),Justyna Kocik-Krol,Bogdan Musielak,Małgorzata Stec,Kazimierz Węglarczyk,Maciej Siedlar,Łukasz Skalniak,Jacek Plewka,Katarzyna Magiera‐Mularz	0
2	Balancing cell cycle arrest and immune activation: A synergistic window for idasanutlin and anti-PD-1 therapy in a syngeneic mouse model 2025 ·Biomedicine & Pharmacotherapy ·(unknown),Małgorzata Statkiewicz,(unknown),(unknown),Alicja Majewska,Justyna Kocik-Krol,Marcin Czepiel,(unknown),Michał Mikuła,(unknown),Tad A. Holak,Łukasz Skalniak	0
3	Therapeutic Responses to Two New SN-38 Derivatives in Colorectal Cancer Patient-Derived Xenografts and Respective 3DIn VitroCultures 2024 ·Anticancer Research ·(unknown),David L. Earnshaw,(unknown),Ewelina Kaniuga,(unknown),Małgorzata Statkiewicz,(unknown),(unknown),Justyna Kocik-Krol,(unknown),(unknown),(unknown),Lech Kozerski,(unknown),Michał Mikuła,Jerzy Ostrowski	1
4	Design, Synthesis, and Biological Evaluation of 2-Hydroxy-4-phenylthiophene-3-carbonitrile as PD-L1 Antagonist and Its Comparison to Available Small Molecular PD-L1 Inhibitors 2023 ·Journal of Medicinal Chemistry ·(unknown),Roberto Butera,Marta Requesens,Annechien Plat,Tryfon Zarganes‐Tzitzikas,Constantinos G. Neochoritis,Jacek Plewka,Łukasz Skalniak,Justyna Kocik-Krol,Bogdan Musielak,Katarzyna Magiera‐Mularz,(unknown),(unknown),Marco de Bruyn,Hans W. Nijman,Philip H. Elsinga,Tad A. Holak,Alexander Dömlingꝉ	9
5	Solubilizer Tag Effect on PD-L1/Inhibitor Binding Properties for m-Terphenyl Derivatives 2023 ·ACS Medicinal Chemistry Letters ·Ewa Surmiak,(unknown),Jacek Plewka,(unknown),Justyna Kocik-Krol,(unknown),(unknown),(unknown),Bogdan Musielak,Monica Viviano,Sabrina Castellano,Łukasz Skalniak,Katarzyna Magiera‐Mularz,Tad A. Holak,Justyna Kalinowska‐Tłuścik	7
6	Biphenyl Ether Analogs Containing Pomalidomide as Small-Molecule Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction 2022 ·Molecules ·Shabnam Shaabani,(unknown),Ewa Surmiak,(unknown),(unknown),Roberto Butera,Tryfon Zarganes‐Tzitzikas,(unknown),Justyna Kocik-Krol,Katarzyna Magiera‐Mularz,Łukasz Skalniak,Alexander Dömlingꝉ,Tad A. Holak	5
7	Terphenyl-Based Small-Molecule Inhibitors of Programmed Cell Death-1/Programmed Death-Ligand 1 Protein–Protein Interaction 2021 ·Journal of Medicinal Chemistry ·(unknown),Ewa Surmiak,Jacek Plewka,Katarzyna Magiera‐Mularz,Justyna Kocik-Krol,Bogdan Musielak,Dominik Sala,Radosław Kitel,Małgorzata Stec,Kazimierz Węglarczyk,Maciej Siedlar,Alexander Dömlingꝉ,Łukasz Skalniak,Tad A. Holak	61
8	PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action 2021 ·International Journal of Molecular Sciences ·Ewa Surmiak,Katarzyna Magiera‐Mularz,Bogdan Musielak,(unknown),Justyna Kocik-Krol,Radosław Kitel,Jacek Plewka,Tad A. Holak,Łukasz Skalniak	27
9	Di-bromo-Based Small-Molecule Inhibitors of the PD-1/PD-L1 Immune Checkpoint 2020 ·Journal of Medicinal Chemistry ·(unknown),Bogdan Musielak,Justyna Kocik-Krol,Łukasz Skalniak,Dominik Sala,(unknown),Katarzyna Magiera‐Mularz,(unknown),(unknown),Małgorzata Stec,Maciej Siedlar,Tad A. Holak,Jacek Plewka	58
10	Human and mouse PD-L1: similar molecular structure, but different druggability profiles 2020 ·iScience ·Katarzyna Magiera‐Mularz,Justyna Kocik-Krol,Bogdan Musielak,Jacek Plewka,Dominik Sala,(unknown),P. Grudnik,(unknown),Marcin Czepiel,Maciej Siedlar,Tad A. Holak,Łukasz Skalniak	58
11	Macrocyclic Peptide Inhibitor of PD‐1/PD‐L1 Immune Checkpoint 2020 ·Advanced Therapeutics ·Katarzyna Magiera‐Mularz,(unknown),Łukasz Skalniak,P. Grudnik,Bogdan Musielak,Jacek Plewka,Justyna Kocik-Krol,Małgorzata Stec,Kazimierz Węglarczyk,Dominik Sala,Benedykt Władyka,Maciej Siedlar,Tad A. Holak,Grzegorz Dubin	8
12	CA-170 – A Potent Small-Molecule PD-L1 Inhibitor or Not? 2019 ·Molecules ·Bogdan Musielak,Justyna Kocik-Krol,Łukasz Skalniak,Katarzyna Magiera‐Mularz,Dominik Sala,(unknown),Małgorzata Stec,Maciej Siedlar,Tad A. Holak,Jacek Plewka	122
13	Helping the Released Guardian: Drug Combinations for Supporting the Anticancer Activity of HDM2 (MDM2) Antagonists 2019 ·Cancers ·Justyna Kocik-Krol,(unknown),(unknown),Ewa Surmiak,Tad A. Holak,Łukasz Skalniak	28
14	Prolonged Idasanutlin (RG7388) Treatment Leads to the Generation of p53-Mutated Cells 2018 ·Cancers ·Łukasz Skalniak,Justyna Kocik-Krol,(unknown),Anna Skalniak,Monika Rak,Agnieszka Wolnicka-Głubisz,Tad A. Holak	51
15	PO-432 Small molecules, peptides and antibodies – the comparison of PD-1/PD-L1 blocking potential in an in vitro immune checkpoint blockade assay 2018 ·ESMO Open ·Łukasz Skalniak,Justyna Kocik-Krol,Katarzyna Guzik,Grzegorz Dubin,Tad A. Holak	3
16	Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint 2017 ·Angewandte Chemie International Edition ·Katarzyna Magiera‐Mularz,Łukasz Skalniak,Krzysztof M. Żak,Bogdan Musielak,Ewa Rudzińska‐Szostak,Łukasz Berlicki,Justyna Kocik-Krol,P. Grudnik,Dominik Sala,Tryfon Zarganes‐Tzitzikas,Shabnam Shaabani,Alexander Dömlingꝉ,Grzegorz Dubin,Tad A. Holak	136
17	Bioactive Macrocyclic Inhibitors of the PD‐1/PD‐L1 Immune Checkpoint 2017 ·Angewandte Chemie ·Katarzyna Magiera‐Mularz,Łukasz Skalniak,Krzysztof M. Żak,Bogdan Musielak,Ewa Rudzińska‐Szostak,Łukasz Berlicki,Justyna Kocik-Krol,P. Grudnik,Dominik Sala,Tryfon Zarganes‐Tzitzikas,Shabnam Shaabani,Alexander Dömlingꝉ,Grzegorz Dubin,Tad A. Holak	5
18	Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells 2017 ·Oncotarget ·Łukasz Skalniak,Krzysztof M. Żak,Katarzyna Guzik,Katarzyna Magiera‐Mularz,Bogdan Musielak,Magdalena Pachota,(unknown),Justyna Kocik-Krol,P. Grudnik,Marcin D. Tomala,(unknown),Krzysztof Pyrć,Alexander Dömlingꝉ,Grzegorz Dubin,Tad A. Holak	221

About Justyna Kocik-Krol

Justyna Kocik-Krol is a scholar working on Oncology, Immunology and Biotechnology, having authored 18 papers that have together received 800 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), CAR-T cell therapy research (11 papers) and Peptidase Inhibition and Analysis (6 papers). The work is most often cited by research in Oncology (617 citations), Immunology (272 citations) and Radiology, Nuclear Medicine and Imaging (122 citations). Justyna Kocik-Krol has collaborated with scholars based in Poland, Netherlands and Hungary. Frequent co-authors include Tad A. Holak, Łukasz Skalniak, Katarzyna Magiera‐Mularz, Bogdan Musielak, Dominik Sala, Jacek Plewka, P. Grudnik, Alexander Dömlingꝉ, Grzegorz Dubin and Maciej Siedlar. Their work appears in journals such as Angewandte Chemie International Edition, International Journal of Molecular Sciences and Journal of Medicinal Chemistry.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact